Semaglutide — mechanism and clinical profile
Semaglutide is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is an incretin hormone released by the intestinal L-cells in response to eating. GLP-1 receptor agonists mimic this signal, producing several metabolic effects: slowing gastric emptying, increasing satiety signaling to the hypothalamus, reducing glucagon secretion, and improving insulin secretion in a glucose-dependent manner.
The practical result is meaningful reduction in appetite and caloric intake. The clinical trial data (SELECT, STEP trials) shows 15-18% body weight reduction in non-diabetic populations at therapeutic doses with sustained treatment.
Semaglutide is available as Ozempic (diabetes indication), Wegovy (weight management indication), and compounded semaglutide.
Tirzepatide — mechanism and clinical profile
Tirzepatide is a dual GIP/GLP-1 receptor agonist. It activates both the GLP-1 receptor (same as semaglutide) and the GIP (glucose-dependent insulinotropic polypeptide) receptor.
GIP acts through a different but complementary mechanism — it affects adipose tissue directly, enhances GLP-1's insulin-stimulating effect, and appears to reduce some of the GI side effects seen with GLP-1-only agonists.
The clinical trial data (SURMOUNT trials) shows 20-22% body weight reduction in non-diabetic populations at therapeutic doses — meaningfully greater than semaglutide in head-to-head comparisons. This difference is real and clinically significant.
Tirzepatide is available as Mounjaro (diabetes indication), Zepbound (weight management indication), and compounded tirzepatide.
The key clinical differences
Magnitude of effect: Tirzepatide produces greater average weight loss than semaglutide in clinical trials — approximately 20-22% vs 15-18% body weight reduction.
GI tolerability: Counterintuitively, tirzepatide is often better tolerated than semaglutide despite its greater potency, likely due to the complementary GIP receptor activity reducing net GI side effects.
Insulin resistance: Both improve insulin sensitivity. Tirzepatide's GIP component has additional effects on adipose tissue metabolism that may be advantageous in patients with significant insulin resistance.
Cost and availability: Both products have had supply variability. Compounded versions of both are available. Cost is comparable at most pharmacies.
When does the choice matter?
For most patients, tirzepatide's superior efficacy and comparable tolerability make it a reasonable first-line choice when either would be appropriate. Semaglutide may be preferred in specific circumstances: established good response on semaglutide, specific insurance coverage situations, or patient preference based on prior experience.
The Revitalize approach
Medication selection within the medical weight loss program is made based on the patient's metabolic profile, insulin resistance pattern, prior medication history, and treatment goals. The conversation about which agent is appropriate happens after a complete metabolic evaluation — not before it. Neither medication is prescribed without the clinical framework of the structured program. The medication is one tool in a protocol that also addresses hormonal status, thyroid function, nutrition architecture, and body composition goals.